Document is current
Any future updates will be listed below
-
Authors
Liu, Yong
Feng, Xuemei
Wang, Juan
Li, Mingfen
- License Information
-
More Information
Article History
Received: 10 May 2024
Revised: 17 May 2024
Accepted: 17 May 2024
First Online: 18 July 2024
CONFLICT OF INTEREST
: The authors of this work declare that they have no conflicts of interest.
: Middle cerebral artery occlusion (MCAO), nitric oxide (NO), inducible nitric oxide (iNOS), lactate dehydrogenase (LDH), C-X-C chemokine receptor type 4 (CXCR-4), monocyte chemoattractant protein-1 (MCP-1), S100 calcium-binding protein B (S-100β) and K<sup>+</sup>-Cl<sup>−</sup> cotransporter 1 (KCC1), total antioxidant capacity (T-AOC), 8-hydroxy-2'-deoxyguanosine (8-OhdG), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione (GSH), malonaldehyde (MDA); cytokines viz., tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), prostaglandin (PGE<sub>2</sub>), Nuclear factor kappa B (NF-κB), B-cell leukemia/lymphoma 2 protein (Bcl-2), Bcl-2-associated protein x (Bax), matrix metallopeptidase (MMP), ischemia-reperfusion (I/R), traditional Chinese medicines (TCMs), 2,3,5-triphenyl tetrazolium chloride (TTC), quantitative real-time polymerase chain reaction (qRT-PCR), reactive oxygen species (ROS), intracellular adhesion molecule-1 (ICAM-1), blood-brain barrier (BBB), mitochondrial outer membrane permeabilization (MOMP), damage-associated molecular patterns (DAMPs).
: Animal protocols were approved by the Administration Committee of Experimental Animals of Yibin No. 4 People’s Hospital, YibinSichuan 644000, China (Approval ID: 238573B of November 12, 2023). The whole animal study was approved from the Yibin No. 4 People’s Hospital (238573B).
